Saturday, May 12, 2012

Weekend Reading:Triple Therapy for Hepatitis C-Maximizing Opportunities and Avoiding Mistakes

Mothers day is tomorrow, but today I'm off to celebrate with a trip to the nursery to pick out the perfect red geranium, followed by a lovely lunch with mom. 

Most weekends this blog offers up a few substantial links to relevant HCV information, click here for previous "Weekend Reading" articles.

For me, this weekend reading session is exciting, with must read information on viral hepatitis from this months special supplementary issue of Gastroenterology. In this issue full text viral hepatitis review articles and commentaries are available through open access. 

To raise awareness of Hepatitis Awareness Month 2012, the Editors of Clinical Infectious Diseases and The Journal of Infectious Diseases have highlighted recent, topical articles, which have been made freely available throughout the month of May. Both journals are publications of the HIV Medicine Association and the Infectious Diseases Society of America.

We Begin With The Special Issue Articles @ Gastroenterology

Every May, Gastroenterology publishes a supplementary issue, the “13th Issue”, that is devoted to a specific topic or theme. When the 2012 theme was discussed by the new Board of Editors (each member of which desperately tried to avoid having his or...

Maximizing Opportunities and Avoiding Mistakes in Triple Therapy for Hepatitis C Virus
Recently developed drugs and innovative strategies for the treatment of chronic infection with genotype 1 hepatitis C virus (HCV) have become the standard of care. The protease inhibitors telaprevir (Incivek) and boceprevir (Victrelis) are the first...

Will Interferon-Free Regimens Prevail?
Many promising small molecule inhibitors directed against hepatitis C virus (HCV) proteins (direct-acting antiviral [DAA] agents) and compounds targeting host cell factors (host-targeting agents [HTAs]) are currently in the drug development and...

New Virologic Tools for Management of Chronic Hepatitis B and C
Molecular biology techniques are routinely used to diagnose and monitor treatment of patients with chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infections. These tools can detect and quantify viral genomes and analyze their sequence to...

Noninvasive Methods to Assess Liver Disease in Patients With Hepatitis B or C
The prognosis and management of patients with chronic viral hepatitis B and C depend on the amount and progression of liver fibrosis and the risk for cirrhosis. Liver biopsy, traditionally considered to be the reference standard for staging of...

HCV Infection and Metabolic Syndrome: Which Is the Chicken and Which Is the Egg?
Hepatitis C virus (HCV) causes chronic hepatitis, which can progress to cirrhosis and hepatocellular carcinoma.1 The World Health Organization estimates that approximately 2.35% of the world population (∼160 million individuals) is infected with HCV.2...

Animal Models for the Study of Hepatitis C Virus Infection and Related Liver Disease
Hepatitis C virus (HCV) causes liver-related death in more than 300,000 people annually. Treatments for patients with chronic HCV are suboptimal, despite the introduction of directly acting antiviral agents. There is no vaccine that prevents HCV...

Is Hepatitis C Virus Carcinogenic?
No one would argue with the notion that chronic infection with hepatitis C virus (HCV) causes hepatocellular carcinoma (HCC). Early observations of the association between post-transfusion non-A, non-B hepatitis and HCC in Japan from the 1980s1 have,..

Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma
Most cases of hepatocellular carcinoma (HCC) are associated with cirrhosis related to chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infection. Changes in the time trends of HCC and most variations in its age-, sex-, and race-specific...

Pathogenesis and Treatment of Hepatitis E Virus Infection
Hepatitis E has been considered to be a travel-associated, acute, self-limiting liver disease that causes fulminant hepatic failure in specific high-risk groups only. However, hepatitis E virus (HEV) infection can also be acquired in industrialized

Will There Be a Vaccine to Protect Against the Hepatitis C Virus?
The discovery of the hepatitis C virus (HCV) more than 20 years ago offered the promise of a vaccine to prevent life-long persistent infection and associated progressive liver diseases. To date, only a few candidate vaccines have been tested in human...

Viral Hepatitis in Liver Transplantation
Liver transplantation is the only alternative for patients with end-stage liver disease. Viral hepatitis B and C are among the most common causes of cirrhosis and hepatocellular carcinoma and a frequent indication for liver transplantation. Hepatitis...

Is Hepatitis Virus Resistance to Antiviral Drugs a Threat?
The onset of the acquired immune deficiency syndrome epidemic in the early 1980s led to successful antiviral drug discovery programs, which brought to the market a large number of antiretroviral drugs with different targets and mechanisms of action....

Effectiveness of Hepatitis B Treatment in Clinical Practice
It is important to examine the effectiveness of current therapies for chronic hepatitis B in clinical practice, given the therapeutic advances over the past 15 years. A 2010 Institute of Medicine report on hepatitis and liver cancer stated that the...

Is There a Role for Ribavirin in the Era of Hepatitis C Virus Direct-Acting Antivirals?
The Protease Inhibition for Viral Evaluation (PROVE) 2 and PROVE 3 trials tested the efficacy of various regimens of telaprevir-combination therapy in treatment-naïve and treatment-experienced patients.1, 2 Both studies included a ribavirin-free arm...

Anti−Hepatitis C Virus Drugs in Development
Development of robust cell culture models for hepatitis C viral infection has greatly increased our understanding of this virus and its life cycle. This knowledge has led to the development of many drugs that target specific elements of viral...

Genetic Factors and Hepatitis C Virus Infection
It is now possible to comprehensively screen the human genome for genetic variation that influences the outcomes of human disease and pharmacotherapy. The most popular approach remains the genome-wide association study (GWAS), in which many hundreds...

Management of Patients Coinfected With HCV and HIV: A Close Look at the Role for Direct-Acting Antivirals
With the development of effective therapies against human immunodeficiency virus (HIV), hepatitis C virus (HCV) infection has become a major cause of morbidity and mortality among patients with both infections (coinfection). In addition to the high...

Clinical Infectious Diseases and The Journal of Infectious Diseases Open Access Articles

Clinical Infectious Diseases articles:
Acute Hepatitis Associated With Autochthonous Hepatitis E Virus Infection—San Antonio, Texas

Factors Associated With Discordance Between Absolute CD4 Cell Count and CD4 Percentage in HIV/Hepatitis C Coinfected Patients

Expanding Access to Treatment for Hepatitis C in Resource-Limited Settings: Lessons From HIV/AIDS

Liver Fibrosis Progression After Acute Hepatitis C Virus Infection in HIV-Positive Individuals

The Cost-effectiveness of Screening for Chronic Hepatitis B Infection in the United States

The Journal of Infectious Diseases articles:
Ribavirin Regulates Hepatitis C Virus Replication Through Enhancing Interferon-Stimulated Genes and Interleukin 8

Serum Hepatitis B Virus-DNA Levels Correlate With Long-term Adverse Outcomes in Spontaneous Hepatitis B e Antigen Seroconverters

Long-term Durability of Immune Responses After Hepatitis A Vaccination Among HIV-Infected Adults

A Randomized Controlled Study of Accelerated Versus Standard Hepatitis B Vaccination in HIV-Positive Patients

Antiviral Activity of Danoprevir (ITMN-191/RG7227) in Combination With Pegylated Interferon α-2a and Ribavirin in Patients With Hepatitis C

No comments:

Post a Comment